Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk PopulationPaul G. Richardson, Joan Bladé, Alessandra Larocca et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 3
HORIZON (OP-106) Study of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Daratumumab and/or Pomalidomide: Updated Efficacy and SafetyPaul G. Richardson, María‐Victoria Mateos, Albert Oriol et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 2